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Abstract  
Preventing chronic disease deterioration is an unmet need in people with multiple sclerosis, where axonal loss is 
considered the key substrate of chronic disability. Clinically, chronic multiple sclerosis often presents as 
progressive myelopathy. Spinal cord cross-sectional area assessed using MRI is associated with increasing 
disability and has, by inference, been proposed as an indirect index of axonal degeneration. However, the 
association between cross-sectional area and axonal loss and their correlation with demyelination have never 
been addressed using comprehensive sampling of post mortem tissue. We extensively sampled whole post 
mortem spinal cords of people with multiple sclerosis and healthy controls to quantify axonal density and its 
association with demyelination and cross-sectional area. 
Whole fixed post mortem spinal cords of thirteen people with multiple sclerosis (seven women, six men; mean 
disease duration= 29.2 years) and five healthy controls were dissected. Tissue blocks were embedded in paraffin 
and immuno-stained for myelin basic protein and phosphorylated neurofilaments. Measurements included total 
cross-sectional area, the areas of (i) lateral cortico-spinal tracts, (ii) grey matter, (iii) white matter, (iv) 
demyelination and the number of axons within the lateral cortico-spinal tracts. Axons above and below a 3µm 
diameter threshold were counted separately. Linear mixed models were used to analyse relationships. 
A total of 396 tissue blocks were used. In multiple sclerosis spinal cord the reduction of cross-sectional area at 
cervical, thoracic and lumbar levels ranged between 19 and 24%, with borderline significance (p=0.055) for the 
largest reduction in the cervical cord. Atrophy of white (19-24%) and grey (17-21%) matter contributed equally 
to this overall reduction with no significant difference across levels. Axonal density in multiple sclerosis 
cortico-spinal tracts was lower by 57-62%, with no evidence of variation across levels (p=0.145). Axonal loss 
equally affected all fibres regardless of diameter. Demyelination affected 24-48% of the grey matter, most 
extensively at the thoracic level, whilst it affected only 11-13% of the white matter, with no significant 
differences across spinal levels. Disease duration was associated with reduced axonal density, however not with 
any area index. Significant association was detected between focal demyelination and axonal density whilst the 
latter did not correlate with the total area of demyelination. 
Within nearly 30 years multiple sclerosis reduces axonal density by about 60% throughout the spinal cord. 
Spinal cord cross sectional area, reduced by about 20%, appears to be a poor predictor of axonal density as no 
association emerged between these two indices. 
 
Keywords: multiple sclerosis; spinal cord; axons; demyelination; atrophy  
 
Abbreviations: CST: Lateral cortico-spinal tract, aCST: cortico-spinal tract area, CDD: chronic disease 
deterioration, CSA: cross sectional area, CoV: coefficient of variation, EDSS: expanded disability status scale, 
GM: grey matter, MBP: myelin basic protein, WM: white matter. 
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Introduction  
 
Multiple sclerosis (MS) is a common inflammatory demyelinating disease of the central nervous system leading 
to chronic disability [32].  The most evident pathologic findings in the CNS of people with multiple sclerosis 
(pwMS) include focal white matter (WM) demyelination and remyelination, inflammation, a variable degree of 
axonal preservation and loss, and gliosis [29] as well as extensive grey matter (GM) tissue damage [27].  
 
The spinal cord is the most frequent location of clinically-apparent pathology at first presentation in pwMS [34]. 
It is also a common manifestation site of chronic disease deterioration (CDD) leading to loss of urinary and 
faecal sphincter control as well as progressive motor and sensory dysfunction of the limbs and trunk resembling 
the clinical syndrome of progressive myelopathy [33]. 
 
Although inflammation and demyelination are important features throughout the disease course, degeneration of 
chronically demyelinated axons is considered the major pathological correlate of CDD [3]. CDD may, at least in 
part, be mediated by mechanisms independent of the inflammatory penumbra associated with relapsing MS 
[2,40,14,1]. The reduction of spinal cord cross-sectional area (CSA), measured using magnetic resonance 
imaging (MRI), is widely considered an indirect measure of axonal degeneration [41,25,29]. 
 
Though axonal loss has been described in MS for over 160 years [5,6,31], a number of fundamental issues 
regarding axonal pathology in the chronic MS spinal cord have remained unresolved. Firstly, the reported 
degree of axonal loss after a life with MS has been highly variable ranging from 19-60% [30,10,15]. Secondly, 
axonal loss in the MS cortico-spinal tracts (CSTs) was found to be size-selective, with small diameter fibres 
more affected than large ones [10]. However, examination of the proportional rather than the absolute loss has, 
to our knowledge, never been undertaken [15,10,38]. Thirdly, the distribution of lesions, degree of axonal loss, 
and reduction of CST [10] and of cross-sectional area (CSA) [19] has been described as uneven across the cord 
length, with most pronounced changes detected in the upper cervical portion of the MS spinal cord . However, 
these findings were based on relatively selective sampling strategies [10,11,20,19 ,18], sometimes leading to 
surprising results, such as the complete lack of GM atrophy after a mean disease duration of 17 years [19] a 
finding challenged by MRI evidence suggesting MS spinal cord GM atrophy as a strong predictor of disability 
[36].  Finally, whilst the role of inflammatory demyelination for axonal damage and loss in acute multiple 
sclerosis is well established [13,39], the association of axonal loss with demyelination in chronic MS has 
remained unclear, with some groups detecting no difference in axonal counts between lesions and non-lesional 
spinal cord [30]. 
 
In order to provide more definitive pathology indices and to explore the potential of spinal cord CSA as a 
predictor of axonal loss, we comprehensively sampled whole post mortem spinal cords from pwMS and controls 
focussing our analysis on: (i) axonal loss in the CSTs (large and small diameter fibres), (ii) presence and degree 
of GM and WM demyelination and atrophy, and (iii) their association with CSA.  
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Materials and Methods 
Whole post mortem spinal cords of pwMS and control subjects who died of non-neurological conditions were 
used. Tissues had been donated through the donor scheme of the UK Multiple Sclerosis Tissue Bank (Research 
Ethics Committee reference number 08/MRE09/31). A single case (MS0) was provided by Professor Joanne 
Martin through the tissue donor programme of The Royal London Hospital (Barts Health NHS Trust, London, 
UK). All tissues were fixed in 4% formaldehyde solution. Clinical notes were reviewed to obtain demographics, 
disease onset and course and to estimate the degree of disability. The quality and the preservation of each spinal 
cord was macroscopically assessed at the beginning of the study by a neuropathologist (FS) to exclude any 
obvious compression or artefactual damage due to tissue handling. 
 
Tissue sampling and immunohistochemistry 
Spinal cord levels were identified based on the presence of the thinnest nerve root at thoracic level 1. The 
remaining nerve roots were subsequently identified and marked. Each cord was then dissected axially to result 
in at least one tissue block per available nerve root level (Fig. 1a). Each tissue block was then marked with 
tissue dye to retain information on its spatial orientation and processed for embedding in paraffin wax. Of each 
tissue block 10μm –thick sections were cut using a Shandon Finesse ME+ microtome (ThermoScientific, UK) 
Care was taken to cut them in a plane perpendicular to the anterior spinal artery. The sections were mounted on 
Superfrost+ slides (VWR, UK) and left in a 60ᵒC oven overnight. The distance between the exit of the second 
thoracic (T2) and fifth lumbar (L5) pair or nerve roots was measured to be used as a ‘proxy’ of total cord length, 
for the statistical analysis of confounding by cord length (see below).  
 
Serial sections of each block were stained for H&E, phosphorylated neurofilaments (SMI-31, mouse 
monoclonal, 1:1000, Abcam, UK) and myelin basic protein (MBP, SMI-94, mouse monoclonal, 1:100, 
Covance, Princeton, NJ, USA) by following a modified protocol [17,38]. To assess microglial activation and 
macrophages a select number of sections was also stained for CD68 (mouse monoclonal, 1:100, Abcam, UK). 
After cutting, sections were dewaxed in xylene and rehydrated in industrial methylated spirit (IMS) and water. 
After antigen retrieval was performed for 10 minutes in citrate buffer at pH6, the sections were left to cool 
before undergoing blocking with 2.5% normal horse serum (Vector Labs, Burlingame, CA) and avidin/biotin 
block (Thermo Fisher Scientific, Waltham, USA). Primary antibodies were incubated for 60 min at room 
temperature followed by appropriate biotinylated secondary antibody incubation for 30 min, which were 
detected using the ABC method (Vector Labs, Peterborough, UK). 3, 3'-diaminobenzidine (DAB) was applied 
for 5 min followed by counterstaining with haematoxylin. Sections were mounted in Di-N-Butyle Phthalate in 
Xylene (DPX, VWR, UK) and left to dry. To enable direct comparison of our results with previous work by 
others [10]we repeated the analysis of axonal density between control and MS using only two randomly selected 
blocks per anatomical region.  
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Area measurements 
Images of cross-sectional whole tissue blocks were acquired using a x4 objective (Fig. 1b-d) using a standard 
microscope (Nikon eclipse 80i) equipped with a motorized stage (mbf bioscience, Williston, USA) and saved as 
TIFF files. Images of sections stained for SMI-31 were opened with ImageJ (version 1.47; 
http://imagej.nih.gov/ij/) to manually outline and measure the following: (i) the CSA, (ii) the areas of GM and 
WM and (iii) the area of the lateral cortico-spinal tract (aCST; Fig. 2a). The latter was outlined following 
anatomic criteria: a horizontal line extended laterally from the most posterior part of the grey matter commissure 
out to the lateral border of the cord, which was used to define the anterior border. The outer margin of the spinal 
cord and the dorsal horn were used as the lateral and medial borders, respectively [10,38,37].  
Measurement of demyelination 
Where present, GM and WM demyelination were manually outlined on MBP images at x4 magnification and 
their area measured. The total areas of GM and WM demyelination in each block containing lesions was 
calculated as the sum of all lesion areas of the respective tissue type in the section (Fig. 1d). GM and WM 
demyelination were then expressed as percentages. Only tissue blocks affected by WM demyelination were used 
for analysis of the relationship between demyelination and axonal loss. 
Assessment of axonal count and density 
Using SMI-31 immuno-stained sections, four images at x40 magnification were randomly acquired from both 
the left and the right cortico-spinal tracts of each tissue block and saved as TIFF files. Care was taken that these 
images, which were subsequently used for quantifying the number of axons, were placed well within the 
acknowledged boundaries of the CST (Fig. 2a). Each image was then opened and a counting frame (sized: 120 
μm x 120 μm) applied (Fig. 2b and c). After adjusting the white balance and transforming the area outlined by 
the counting frame to 8-bit black and white, axons were detected using ImageJ applying an object detection 
threshold to quantify the number of large (sized >3μm) and small (sized ≤3μm) diameter axons separately 
[10,30] (Fig. 2d and e). 
 
Axonal density in each CST was calculated as the sum of large and small diameter axons divided by the total 
area of the four counting fields expressed as the number of axons/mm2. Given no significant difference was 
detected between left and right CST axonal densities, the density of axons per tissue block was then expressed 
as a mean of left and right for all the subsequent statistical analysis. 
 
Reproducibility of our histological measurements was verified by repeating three times the quantification of 
axonal density in one tissue block at each cord level (cervical, thoracic and lumbar) in six cases (three MS and 
three controls) by N.P. The coefficient of variation (CoV) was calculated as the square root of the mean 
variance, divided by the mean of the measurements. 
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Analysis of focal demyelination and axonal loss  
 
Blocks containing ‘isolated’ WM lesions were obtained irrespective of the spinal cord proportion (cervical, 
thoracic, lumbar), and the following criteria applied: lesions were considered isolated if the CSTs appeared 
normally myelinated in at least 5 adjacent blocks (each approximately ~0.5cm thick) above and below the 
lesion.  Regions of interest were then placed in the lesion, and (i) corresponding ipsilateral areas of non-lesional 
tissue that included the pathway of the CST in the block immediately above and below the lesion, as well as (ii) 
homotopic contralateral areas of non-lesional tissue at each corresponding level (lesion block, above lesion 
block, below lesion block). Axonal density was established as described above, and compared amongst groups 
(Fig. 3).  
 
Statistical analysis 
Differences between patients and controls were examined using linear mixed models with the measure being 
compared as the response variable and a fixed effect group indicator; fixed effect cord region indicators were 
included in all models, and other potential confounders (age at death dichotomised at <66, 66+ years to give 
roughly equal numbers, gender and cord length, dichotomised at <29, 29+ cm) were included singly as fixed 
effect covariates. These models used the cord slice as the unit of analysis, with a random subject intercept to 
account for the ownership of slices by subjects. An advantage of the mixed model is that it enables all available 
cord slices to be used in the analyses. Possible variations in patient vs control differences by region were 
examined by adding a group  region interaction term to the models. Linear mixed models were also used to 
investigate associations between cord measures and potential confounders. Residuals were examined to check 
model assumptions, as a result of which axonal density was log transformed to improve residual normality and 
homoscedasticity; this has two consequences: i) the calculated estimates and their confidence intervals represent 
proportional, not absolute loss; ii) it suggests that proportional loss in axonal density may be a more reliable 
description of patient vs control difference than absolute loss. Restricted maximum likelihood estimation 
(REML) was used except where there was evidence of residual heteroscedasticity, when maximum likelihood 
was used with robust standard errors. Analyses were performed in Stata 13 (Stata Corporation, College Station, 
Texas, USA), all measures were reported as average ± standard deviation (SD), except where noted. 
Significance is reported at 5%, unless otherwise indicated. 
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Results 
 
Subjects 
Post mortem tissue of eighteen subjects, thirteen (seven women, six men) with MS and five people (three men 
and two women) with no evidence of neurological disease, who donated their CNS to the UK MS Tissue Bank, 
was used (Table 1). The mean age at death of pwMS was 65.3 ± 11 years and for healthy controls 82 ± 7 years. 
Disease duration in pwMS was 29.2 ± 11.2 years. None of the patients had been treated with disease modifying 
drugs. 
 
Spinal cord preservation and microscopic tissue features  
The wet tissue was of good quality with no macroscopically evident signs of compression and/or other 
artefactual damage. The samples had been fixed in formalin for 30 ± 24 months before processing. The time 
between death and tissue fixation was 35.5 ± 16.5 hours. The mean cord length of all spines was 27.2 ± 4.8 cm, 
with controls being 28.5 ± 4.4 cm and MS being 26.8 ± 5.0 cm. The number of tissue blocks analysed ranged 
from 17 to 35 in controls and from 11 to 32 in MS. In total 396 tissue blocks were used for in this study. A 
shrinkage factor was not established in the current experiment, however a recent study pursued in our lab 
investigating cortical MS pathology revealed a shrinkage factor of 30% years [4], which is virtually identical to 
a previously reported factor in the spinal cord [10].  
Assessment of cellularity 
H&E and CD68 (immuno-) stained sections were used for inspection of MS and control tissue. Characteristics 
of the cellular composition were assessed in areas that included the CST (Fig. 4). Whilst within MS lesions 
cellularity was decreased compared to the surrounding non-lesional tissue, the latter was indistinguishable from 
control tissue with no change in cellularity suggestive of inflammation. CD68 immuno-staining did not reveal 
any difference between lesional and non-lesional MS tissue. Against this backdrop, no systematic assessment of 
inflammatory cells was undertaken. 
 
Reproducibility of histological indices 
The calculation of the CoV for the aCST measurement, plotted as an average per slide between the left and right 
CSTs and combining all spinal levels for both patient and control tissue, was 10%. When separating the same 
measurement by level and testing for significant differences the CoV was 10% at cervical, 11% at thoracic and 
4% at lumbar level with no evidence of patient versus control difference in measurement error (p=0.35). The 
CoV for the axonal density, when plotted as an average combining all regions and both patient and control 
cases, was also 10%. A separate analysis by level showed a significantly lower variability at the cervical level 
(6%, p=0.0008) when compared to thoracic (13%) and lumbar (10%). There was no evidence of patient versus 
control difference in measurement error (p=0.829). 
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Spatial distribution of tissue loss along the multiple sclerosis spinal cord 
Table 2 shows unadjusted patient vs control differences by spinal cord levels. The multiple sclerosis spinal cord 
CSA was lower than control by between 19% and 24%, quite small proportional variation between cord levels; 
however, there was borderline significant evidence, p=0.055, of variation in absolute differences by region, with 
the largest absolute loss in the cervical region (Fig. 5a). 
 
aCST was decreased in the multiple sclerosis spinal cord by between 25% and 37% (Table 2). There was 
significant evidence of variation in absolute differences across spinal cord levels, p= 0.017. The greatest 
absolute reduction was observed at thoracic, followed by cervical level (Fig. 5b). 
 
GM area differences across the spinal cord showed a reduction in multiple sclerosis spinal cord ranging from 
17% to 21%. There was only borderline significant evidence that the absolute differences varied across the three 
levels of the neuraxis, p= 0.0515. All values are shown in Table 2 and plotted in Fig. 5c.  
 
The pattern of WM area across the spinal cord showed a reduction in multiple sclerosis varying from 19% to 
24%. There was no significant evidence of variation in absolute differences by region (p= 0.165). All values are 
shown in Table 2 and Fig. 5d.  
 
Adjustment for age, gender or cord length did not materially alter estimated differences. 
 
Axonal loss affects all spinal cord levels equally and is independent of axonal 
diameter 
Axonal density in the multiple sclerosis cortico-spinal tract was significantly reduced by between 57% and 62% 
(Table 3, Fig. 6a), with no evidence of variation in this loss across spinal cord levels (p=0.145).  These estimates 
were obtained using the log transformed density, which better satisfied normality assumptions than the raw 
density.  There were similar reductions in both large and small diameter axons in multiple sclerosis spinal cords 
of  60.6% (large) and 60.2% (small), with no evidence that the proportional reduction in small diameter axons is 
greater than in those with a large diameter, p=0.973 (Fig. 6b and c). These estimates were not materially 
affected by adjustment for age, gender or cord length.  
Assessing the extent of axonal loss using only two blocks per anatomical region showed that the axonal density 
was reduced by 64% at the cervical, 66% at the thoracic and 64% at the lumbar level. Only marginal, not 
statistically significant, difference in the percent change of axonal density between control and MS was detected 
compared to the analysis including all tissue blocks (see above).  
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Grey matter demyelination is more extensive than white matter demyelination  
When analysing only tissue blocks that contained ‘any’ area of GM demyelination its percentage ranged from 
24% to 48% (Fig. 6d, Table 3b), with evidence of a significant variation across the three spinal cord levels 
(p=0.001), with the most extensive GM demyelination affecting the thoracic level. Thoracic GM demyelination 
was significantly greater than at both cervical (p=0.001) and lumbar (p=0.018) levels. 
 
Focusing on tissue blocks that contained ‘any’ area of WM demyelination only its percentage ranged from 11 % 
to 13%, with no evidence of variation across the three cord levels (p= 0.936). (Fig. 6e, Table 3b) 
 
Across the multiple sclerosis spinal cord GM demyelination as a percentage of total GM was more extensive 
than WM demyelination; including all cord levels the mean percent difference between GM and WM 
demyelination was 26% (95% CI 15.4, 36.7, p<0.001). Region-specific percent differences between GM and 
WM demyelination are shown in Table 3b. 
 
Axonal density correlates with disease duration 
In multiple sclerosis, after adjusting for region, higher axonal density was borderline significantly associated 
with shorter disease duration (p=0.055). Disease duration did not correlate with cortico-spinal tract, GM or WM 
area. After adjusting for subject group and region, no significant association was detected between cord length 
as well as age at death and (i) axonal density, (ii) cortico-spinal tract, and (iii) GM or WM areas. No significant 
correlation emerged either between axonal density and (i) aCST and (ii) CSA (Fig. 7a and b). 
 
Axonal loss is strongly associated with focal white matter demyelination, however 
overall lesion volume does not reflect this 
In 10/13 cases included in this study, 11 ‘isolated’ lesions were identified. Focusing on the analysis within CSTs 
affected by an isolated lesion revealed that axonal density within and below these lesions was lower by 49% and 
40%, respectively, compared to the density measured above the lesions (p<0.001). Homotopic contralateral 
areas showed no difference between the two sides above the lesion level, however significant decrease at the 
lesion level (-47%) and below (-42%; p<0.001) (Table 4, Fig. 7c). Including all blocks in which WM 
demyelination was detected no association emerged between the total extent of WM demyelination and axonal 
loss (Fig. 7d). 
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Discussion 
Although axonal loss in MS has been described as a pathological hallmark contributing to functional disability, 
results reporting the extent of axonal pathology have been inconsistent. Whilst this may be due to differences 
among tissue collections, other limitations including sampling bias may have contributed to variable results 
reported [10,30,3,37,15].  We therefore employed a comprehensive sampling strategy to investigate axonal loss 
and its relationship with volume changes and demyelination across the whole spinal cord in multiple sclerosis. 
 
Our CSA measurements indicate that in chronic MS spinal cord atrophy of approximately 20% occurs and that 
this atrophy evenly affects all levels of the spinal cord. No material difference was detected between the spinal 
cord levels when analysing GM and WM atrophy separately. The WM loss detected was between 15 % and 21% 
whilst GM loss was approximately 17% at cervical and lumbar levels, with similar trend difference at the 
thoracic level. Area reduction was also detected specifically affecting aCST, though this was statistically 
significant only at the cervical and thoracic levels. The degree of aCST reduction at the thoracic level (36.5%) 
suggests that the loss of CST fibres may be disproportional to the overall spinal cord atrophy, which affected all 
areas equally. 
 
 
Axonal density was reduced by 57-62% across all levels of the spinal cord. This degree of axonal loss across the 
entire spinal cord is remarkably similar to the loss reported by Tallantyre and co-workers [37] (based on a single 
cervical cord section), approximately twice the loss reported by de Luca and co-workers [10] (five sections in 
total at cervical, thoracic and lumbar levels), and about 1/3 higher compared to Ganter and co-workers [15] (two 
sections at levels C3 and T2). In addition, the cohorts of MS cases used in these three studies had an average 
disease duration of 25, 17 and 14 years, respectively, while it was 29 years in our cohort, suggesting that axonal 
loss accrual is indeed proportional to clinical progression duration. This interpretation is also supported by the 
fact that in our cohort, and after adjusting for anatomical and clinical confounders, the longer was the 
progression the lower was the axonal density within the CSTs.  
 
 
MRI-derived spinal cord atrophy indices are increasingly being used in studies [26], including treatment trials 
(NCT00731692), of people with CDD due to multiple sclerosis. However, despite sufficient statistical power, no 
association emerged in our study between CSA and axonal density (Fig. 7) and the significant difference 
between CSA reduction (20%) and axonal loss (about 60%) suggests spinal cord atrophy significantly 
underestimates the degree of axonal loss, a putative key substrate of CDD. These findings corroborate 
observations in animal models of MS in which the time courses was monitored [21]. Whilst previous studies 
using human post mortem MS samples have investigated CSA changes [19] and axonal loss [15, 3, 30, 10, 11, 
39], correlation between CSA and axonal density has, to our knowledge, never been systematically explored.  
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If spinal cord volume does not provide a straightforward correlate of axonal density, other factors need to be 
considered. The expected degree of atrophy based on axonal loss could be offset by ‘space filling’ tissue 
components such as oedema, inflammation and gliosis. For example, in a clinical study of the sodium channel 
blocker lamotrigine pseudo-atrophy (here: of the brain) due to anti-oedematous effects confounded the detection 
of a (putative) neuroprotective effect [24]. However, although in our study fluid was removed as a result of 
tissue processing and fixation, it is unlikely that oedema would account for the large difference detected 
between CSA and axonal density. Gliosis is a rather more likely candidate given it evidently counteracts the 
space reducing effect of nerve fibre loss [21].  Taken together, these observations suggest that spinal cord 
atrophy is only partially reflective of the pathological feature considered crucial for CDD, i.e. axonal loss. 
Translated into the clinical setting of pwMS, rather than relying on atrophy measures (alone), there appears to be 
an urgent need for better techniques reflecting axonal damage in the spinal cord [16]. 
 
Contrary to earlier studies no difference in the degree of axonal loss between large and small diameter axons 
(p=0.973) was detected, questioning the selective vulnerability of small diameter axons as previously suggested 
[38,10,30]. It was not possible for us to verify whether respective data in previous studies were normally 
distributed. However, analysing the entire spinal cord and applying log transformation to improve residual 
normality and homoscedasticity of our not-normally distributed data suggests that axons of all sizes are equally 
affected. 
 
It should be kept in mind, however, that axonal diameter may decrease in the process of neurodegeneration [22], 
possibly due to a decrease in neurofilament gene and nerve growth factor receptor expression [35]. It is 
therefore possible that large diameter axons in chronic MS become atrophic over the course of the disease. As a 
result, the number of small diameter axons detected may consist of both axons that always were of small 
diameter as well as large diameter axons that have become atrophic. 
 
In line with previous studies, demyelination was significantly more extensive in the GM than the WM, 
underlining the nature of MS as a condition that affects all CNS tissue compartments [20,18] and evidently 
rendering the previously held belief that MS is a merely ‘white matter’ disease outdated. Several groups 
reported a lack of association between demyelination and axonal loss in the MS spinal cord, a surprising result 
given the (multi-) focal nature of the disease [11,38,30,15]. Even in studies employing a highly focussed 
approach, differences in axonal density within and outside lesions did not always emerge [30].  
 
Whilst the overall plaque load in our study did not correlate with the total extent of axonal loss, we detected 
reduced axonal density, by 49%, in focal CST lesions and the associated distal non-lesional CST (Wallerian 
degeneration). Evidence suggests acute axonal damage [14,39] and Wallerian degeneration [12] are 
characteristic features of newly emerging lesions. Our data indicate that even in the very late stage of MS spinal 
cord demyelination has significant impact on tract specific axonal loss distal to lesions, whereas ‘dying back’ 
neuropathy, as previously suggested, seems of lesser importance [7]. 
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The apparent discrepancy between analysing our data using (i) all blocks containing demyelination and their 
associated axonal density and (ii) only blocks containing lesions that affect the CST may have been due to at 
least two factors. Firstly, in the former analysis we included the total area of demyelination, i.e. including areas 
outside the CST, whilst axonal density was established in the CST only. This may have masked the effect of 
focal demyelination on axonal density. Secondly, although we comprehensively examined the entire length of 
the spinal cord, we were unable to account for the potential effects of supra-spinal (brain) tissue pathology on 
spinal cord axonal density. 
 
The effect of focal demyelination on CST axonal loss in our and previous studies [37] are quite different from 
those reported by Lovas and co-workers who did not detect reduction in axonal density, but in axonal thickness 
[38,30]. Our data suggest differences in the methodology of quantification may explain these discrepancies. 
Whilst we are not aware whether Lovas, et al. excluded any lesion pathology above or below their lesion of 
interest we confirmed the absence of tract specific demyelination in five tissue blocks above and below the 
index lesion in our ‘isolated lesion’ experiment. We thereby significantly increased the likelihood that remote 
effects of demyelination did not bias our measurements. An additional, or alternative, explanation could be 
differences in lesion size with longer lesions hypothetically being more damaging, as has been described using 
MRI in people with optic neuritis [23]. However, lesion size was not assessed, neither in our, nor to the best of 
our knowledge in previous post mortem studies. There could be merit adding such measures in the future to 
provide further insights into the effect of demyelination on axonal density. 
 
The lack of a significant difference in the detected axonal loss when including only two tissue blocks per 
anatomical region compared to the analysis of all tissue blocks produced suggests that to investigate axonal loss 
in isolation two blocks per anatomical level appear to be sufficient. However, sampling the entire cord not only 
enables the total magnitude of other pathological features to be assessed, but also to rule out remote effects on 
specific areas of interest, such as in our ‘isolated’ lesion analysis. Such lesions were also quite rare underpinning 
the merit of dissecting the entire cord, though MRI guidance may be an alternative solution as has been shown 
before for sampling lesions in the post mortem brain [8]. 
 
The association detected between axonal density and disease duration suggests time is a key determinant of 
clinically significant tissue damage in chronic MS. Although our data have been obtained using post mortem 
material, in vivo evidence of brain atrophy assessed using MRI suggests that a chronic “slow burning” 
axonopathy may be a feature of MS from the earliest stages of its evolution [10], over and above lesion-
associated acute axonal damage [13,39,14]. This may be triggered by the inflammatory responses that drive 
relapsing attacks, as seen experimentally [21]. However, these smouldering lesions increase with disease 
duration and chronicity in MS and probably contribute to worsening disability [14]. 
 
In conclusion, our study provides robust evidence that after a life with MS for, on average, nearly 30 years about 
60% of spinal cord CST axons are lost. It is likely this loss is an important driver of disease deterioration and 
permanent disability in pwMS and affects axons of any calibre throughout the length of the spinal cord. The 
Field Code Changed
Field Code Changed
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magnitude of spinal cord atrophy, about 20%, does not reflect well the degree of axonal loss, which in itself 
appears strongly associated with focal demyelination. MRI indices of spinal cord volume obtained in vivo are 
likely to underestimate the extent of axonal damage thereby limiting the role of such indices as a treatment 
outcome in clinical trials. New techniques that are more specific for the underlying tissue damage are warranted 
[16]. 
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Table legends 
 
Table 1 Clinical details of all cases. 
 
 
Table 2 Area measurements [mm2], relative and percent difference across spinal cord levels between multiple 
sclerosis and controls. 
 
Table 3 Differences in (a) axonal density between normal control and multiple sclerosis, and (b) percent 
demyelination between grey and white matter in multiple sclerosis 
 
Table 4  Mean axonal density in a) the lesion site and the two sites corresponding to the normal-appearing white 
matter directly above and below the lesion site on the ipsilateral side of the lesion and the corresponding 
contralateral sites on the same blocks, and b) differences in axonal density on the ipsilateral side of the lesion 
compared between the three positions, above the lesion, inside the lesion and below the lesion.   
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Figure legends  
 
Fig. 1 Tissue sampling and quantification of cross sectional area and demyelination   
(A) Spinal cord dissection: after identifying and numbering nerve roots, pictures were taken and the distance 
between thoracic level 2 and lumbar level 5 recorded. Axial blocks were then dissected at each nerve root level. 
At the thoracic level an additional block was dissected between nerve roots (see examples T5A and T5B). Scale 
bar: 1.5cm. (B) Control cervical cord section immuno-stained for SMI-31 at x4 magnification. The grey matter 
(GM) is outlined in red and the cross-sectional area (CSA) in blue. White matter (WM) was calculated as the 
difference between CSA and GM area. (C) Control upper thoracic cord section at x4 magnification stained for 
myelin basic protein (MBP). GM borders are outlined in red. (D) Multiple sclerosis upper thoracic cord section 
stained for MBP. Four WM (WM Lesions 1-4) and one GM lesions (GM Lesion 1, green contour) were 
manually outlined. Scale bar: 1mm 
 
Fig. 2 Assessment of the lateral cortico-spinal tract area and axon counting 
(A) The area of the lateral cortico-spinal tract was manually outlined on SMI-31 immuno-stained sections (blue) 
at x4 magnification as previously described by DeLuca and colleagues.  An area of interest (AOI, black) was 
then placed well inside the anatomical boundaries of the cortico-spinal tract. Within the AOI four frames 
(yellow squares) were then randomly cast and images acquired at x40 magnification. Scale bar: 1mm. These 
SMI-31 images of control (b) and multiple sclerosis (c) spinal cord were opened using ImageJ. One counting 
field (120μm x 120μm, red squares) was placed inside each image. Scale bar: 50μm. Magnified counting frames 
were converted into black & white (8 bit) of control (d) and multiple sclerosis (e) cortico-spinal tract, and axons 
counted at x40 magnification. Scale bar: 25μm. Orange and green arrows indicate large and small diameter 
axons, respectively 
 
Fig. 3 Focal demyelination and axonal loss in the spinal cord cortico-spinal tract 
Myelin basic protein (MBP) stained sections showing the non-lesional CSTs on the blocks directly above (a) 
and below (c) the isolated lesion, as well as the demyelinated CST on the level of the plaque (b). Sequential 
sections stained with SMI-31 are shown for the three levels in g to i respectively in low magnification. Red 
circles show the CST boundaries on the homotopic, ipsilateral side of the lesion, while black circles show the 
CST boundaries on the contralateral, functionally identical, side of the lesion. The four yellow squares in each 
CST represent the four counting fields cast in each CST as described in the methods and Figure 2, where axonal 
density was counted. Scale bar: 1mm. Examples of SMI-stained images from one of the four counting fields on 
the contralateral side of the lesion are shown on high magnification in d, e and f for each of the three regions. K 
shows one example counting field from the lesional CST, while j and l correspond to the counting field 
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examples directly above and below the lesional CST respectively, on the ipsilateral side of the lesion. Scale bar: 
50μm 
 
Fig. 4 Assessment of cellularity and inflammation in control, non-lesional and lesional CSTs 
Low magnification images of MBP (a and h), H&E (c and j) and CD68 (f and m) show the staining patterns in 
MS and control tissue respectively, while a lesional CST is shown on the left highlighted in the red circle and a 
non-lesional CST is shown in black on the right side of the MS image on panel a. Scale bar: 1mm. High 
magnification images of H&E are shown b and d for the lesional and non-lesional CSTs in MS respectively, 
while control images are shown in i and k on the left and the right normal-appearing CST tissue. Examples of 
CD68 staining in high magnification for the plaque and normal-appearing CST are shown in e and g 
respectively, while control staining is shown in l and n. Scale bar: 25μm. 
 
Fig. 5 Area indices across spinal cord levels in multiple sclerosis and controls 
(A) Cross sectional area (CSA) in multiple sclerosis was reduced at the cervical, thoracic and lumbar (p= 0.055) 
levels. (B) The area of the lateral cortico-spinal tract (aCST) was reduced at the cervical and thoracic levels, 
with trend difference at the lumbar level (p= 0.099). (C) The grey matter (GM) area was reduced in multiple 
sclerosis at the cervical and lumbar levels. (D) The white matter (WM) area was reduced at the cervical and 
thoracic levels. Each dot represents one tissue block. Error bars represent standard deviations and stars indicate 
significance levels (***p<0.001; **p< 0.01; *p<0.05). See also Table 2 
 
Fig. 6 Axonal loss and demyelination in the multiple sclerosis spinal cord 
Axonal density was reduced in multiple sclerosis spinal cord when including all (a), small diameter (≤ 3µm) (b) 
and large diameter (>3 µm) (c) axons across all levels. (D) The degree of GM demyelination was higher at the 
thoracic level when compared to the cervical and lumbar levels. (E) No significant difference was detected in 
the extent of WM demyelination between spinal cord regions. Each dot represents one tissue block. Error bars 
represent standard deviations and, stars indicate significance (****p<0.0001; *p<0.05) 
 
Fig. 7 Association between axonal density and focal CST demyelination, axonal density and total white 
matter demyelination and cross-sectional area 
No correlation was detected in multiple sclerosis spinal cord between axonal density and (a) aCST or (b) CSA. 
Focal demyelination affected axonal density locally (p<0.0001) and on the non-lesional CST area directly below 
the plaque (p<0.0001), while it had no effect on either the non-lesional CST above the lesion, or the normal 
appearing white matter on the contralateral side of the lesion in any level (c). Although axonal loss was affected 
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by focal demyelination, it did not have a significant correlation with overall WM demyelination (d). Error bars 
represent standard deviations and, stars indicate significance.  
 
